Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.33 USD
Change Today 0.00 / 0.00%
Volume 0.0
RVALL On Other Exchanges
As of 8:10 PM 06/24/15 All times are local (Market data is delayed by at least 15 minutes).

reva medical inc - cdi (RVALL) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - $0.45
52 Week Low
09/15/14 - $0.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REVA MEDICAL INC - CDI (RVALL)

Related News

No related news articles were found.

reva medical inc - cdi (RVALL) Related Businessweek News

No Related Businessweek News Found

reva medical inc - cdi (RVALL) Details

REVA Medical, Inc., a development stage medical device company, focuses on the commercialization of minimally invasive medical devices for the treatment of coronary artery disease in the human heart. It is developing and testing a bioresorbable stent to treat vascular disease in humans under the Fantom scaffolds name. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

51 Employees
Last Reported Date: 05/14/15
Founded in 1998

reva medical inc - cdi (RVALL) Top Compensated Officers

Co-founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $430.5K
President and Chief Operating Officer
Total Annual Compensation: $447.1K
Chief Financial Officer and Company Secretary
Total Annual Compensation: $515.2K
Senior Vice President of Clinical and Regulat...
Total Annual Compensation: $353.7K
Senior Vice President of Product Development
Total Annual Compensation: $348.7K
Compensation as of Fiscal Year 2014.

reva medical inc - cdi (RVALL) Key Developments

REVA Medical, Inc. Releases Initial Clinical Results for Fantom Scaffold

REVA Medical, Inc. released initial clinical data on a subset of patients treated with the Fantom sirolimus-eluting bioresorbable scaffold at the Paris Course on Revascularization (EuroPCR). The FANTOM I pilot clinical trial, which enrolled patients with the Fantom scaffold at two clinical sites in Brazil and Poland, was designed to provide early clinical data on the device. In these patients acute performance was demonstrated with 100% technical and procedural success and no reported Major Adverse Cardiac Events (MACE) to date, with no incidence of ischemic target lesion revascularization (TLR), myocardial infarction (heart attack) or stent thrombosis. REVA is currently enrolling patients in the FANTOM II trial, which is designed to provide the necessary data for a European CE Mark application of Fantom.

REVA Medical, Inc. expected to report Q2 2015 results on July 30, 2015. This event was calculated by Capital IQ (Created on May 17, 2015).

REVA Medical, Inc. expected to report Q2 2015 results on July 30, 2015. This event was calculated by Capital IQ (Created on May 17, 2015).

Reva Medical, Inc. Expands FANTOM II Clinical Trial to Australia

REVA Medical, Inc. announced that the FANTOM II clinical trial is now enrolling patients with the Fantom sirolimus-eluting bioresorbable scaffold in Australia. This is in addition to previously announced sites in Brazil and Europe. The Fantom scaffold, made from REVA's advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time. The FANTOM II trial is enrolling patients to support a European CE Mark application, which is expected to occur by mid-2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVALL:US $0.33 USD 0.00

RVALL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVALL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RVALL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVA MEDICAL INC - CDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at